Medicare Part B suppliers may deliver the initial immunosuppressive drugs prescribed to a beneficiary after a transplant procedure to an address other than their home to ensure timely access to the medications at discharge, the Centers for Medicare & Medicaid Services announced last week in updated guidance. “In certain cases, a beneficiary who has received a transplant does not return home immediately after discharge,” the guidance states. “In order to ensure timely beneficiary access to prescribed immunosuppressive medications at the time of discharge, suppliers may deliver the initial prescriptions of a beneficiary’s immunosuppressive drugs to an alternate address, such as the transplant facility or alternative location where the beneficiary is temporarily staying, for example, temporary housing, instead of delivering the drugs to the patient’s home address.” AHA advocated for the policy change.

Related News Articles

Perspective
Two weeks ago, I wrote about the
Headline
The U.S. Court of Appeals for the District of Columbia Circuit reversed the voiding of a rule that included Medicare and private insurance payments when…
Headline
The AHA today voiced support for the Improving Seniors’ Timely Access to Care Act (H.R. 3107), bipartisan legislation that would establish requirements for the…
Headline
Medicare will cover nationally Chimeric Antigen Receptor T-cell therapies approved by the Food and Drug Administration to treat certain cancers, as well as off…
Headline
Offering a government insurance program reimbursing at Medicare rates as a public option on the health insurance exchanges could place as many as 55% of rural…
Headline
The Centers for Medicare & Medicaid Services will discontinue the Medicare Advantage Qualifying Payment Arrangement Incentive Demonstration due